Key Highlights

  • Resonance Health shares traded at $0.072, down 12.20%, during the 27 October 2026 trading session.
  • FY26 Revenue was $15.8 million, up 42%, with normalised EBITDA of $2.6 million.
  • Preliminary liver fibrosis device results are based on 50 subjects from a single site.

Shares in Resonance Health Ltd (ASX:RHT) were trading at $0.072, down 12.20%, during the 27 October 2026 trading session, while the S&P/ASX 200 index was at 8,852.80, up 0.49% (42.90 points), at 3:40 pm GMT+11. Resonance Health is an ASX-listed healthcare company with imaging analysis and clinical trial services and a liver fibrosis device in development. The company’s most recent document in the materials reviewed is an October 2026 presentation on preliminary study results and a Capital raising.

FY26 Performance and FY27 Guidance (October 2026)

In its October 2026 presentation, Resonance Health reported FY26 revenue of $15.8 million, up 42% on FY25, normalised EBITDA of $2.6 million (a 16% margin) and statutory net profit after tax of $1.5 million. Operating cash inflow was $2.9 million, and net cash was $2.3 million at 30 June 2026.

FY27 guidance is for revenue of $17 million to $22 million and EBITDA of $2.6 million to $3.6 million, excluding any revenue from the fibrosis device, acquisitions and new sites.

Fibrosis Device and Placement

The presentation covers preliminary results of an extended proof-of-concept study of a non-invasive MRI-based liver fibrosis device. The company stated the results are preliminary, not independently verified, based on 50 subjects from a single site with a broad range of clinical conditions including liver cancer, and that the device is investigational and not cleared for clinical use in any jurisdiction.

The material was prepared in connection with a Placement of new fully paid ordinary shares and is not for distribution in the United States.

Sector Context

The broader market was higher during the session, with the S&P/ASX 200 index was at 8,852.80, up 0.49% (42.90 points), at 3:40 pm GMT+11. Diagnostics and medical device companies report commercial progress through customer sites, product revenue and clinical study enrolment.

Resonance Health shares were trading at $0.072, down 12.20%, against a benchmark gain of 0.49%, a gap of 12.69 percentage points. The figures are session data recorded while the market was open and can change before the market finishes trading.

Risks

The device results are preliminary and may change as data are added, and the device is not cleared for clinical use. The presentation notes the placement and general Investment risks.

What Lies Ahead

The presentation points to completion of the placement, further study data on the fibrosis device and delivery of the FY27 guidance.

Final Takeaway

Resonance Health shares fell during the session. The latest material describes profitable FY26 results alongside a placement and preliminary device data.